Riana Therapeutics GmbH, a spin-off from Vetmeduni Vienna founded this year, has entered into a collaborative agreement with the Lead Discovery Center GmbH (LDC) to support its efforts to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).